CompanyGraph
Shanghai Rightongene Biotechnology Co., Ltd.
688217 · SSE · China
rightongene.comFinancials as of FY2025
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $189.77M, lower than 95% of all stocks globally
- PositionDebt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.76%
Annual Rate
CNY 0.17Paid unknown
Payout Ratio
0.0%Sustainable
Last Ex-Dividend
Oct 24, 2025
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.28BCNY189.77M · vs all stocks (USD)
Revenue (TTM)
162.81MCNY24.13M · vs all stocks (USD)
Profit Margin
-36.06%vs Biotechnology peers
Beta
0.3410xvs all stocks
52-Week Change
-15.67%vs all stocks
Forward Annual Dividend Yield
0.76%vs all stocks
Market Capitalization
1.28BCNY189.77M · vs all stocks (USD)
Enterprise Value
1.01BCNY149.64M · vs all stocks (USD)
Forward P/E
73.23xvs Biotechnology peers
Price to Sales (TTM)
7.77xvs Biotechnology peers
Price to Book (MRQ)
1.49xvs Biotechnology peers
Enterprise to Revenue
6.20xvs Biotechnology peers
Enterprise to EBITDA
-65.22xvs Biotechnology peers
Gross Margin
78.36%vs Biotechnology peers
Profit Margin
-36.06%vs Biotechnology peers
Operating Margin
-23.34%vs Biotechnology peers
Return on Assets (TTM)
-3.29%vs Biotechnology peers
Return on Equity (TTM)
-7.85%vs Biotechnology peers
Revenue (TTM)
162.81MCNY24.13M · vs all stocks (USD)
Revenue per Share (TTM)
2.95CNYUpdated Jul 16, 2026Quarterly Revenue Growth
-28.70%vs Biotechnology peers
Gross Profit (TTM)
118.55MCNY17.57M · vs all stocks (USD)
EBITDA (TTM)
31.13MCNY4.61M · vs all stocks (USD)
Net Income (TTM)
-58.72MCNY-8.70M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-31.92%vs Biotechnology peers
Operating Cash Flow (TTM)
36.73MCNY5.44M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
16.67MCNY2.47M · vs all stocks (USD)
Forward Annual Dividend Rate
0.1700CNYUpdated Jul 16, 2026Forward Annual Dividend Yield
0.76%vs all stocks
Trailing Annual Dividend Rate
0.00CNYUpdated Jul 16, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
1.35MCNYFY2025 · Dec 31, 2025Revenue
177.26MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
43.64MCNYFY2025 · Dec 31, 2025Gross Profit
133.62MCNYFY2025 · Dec 31, 2025Operating Income
-11.00MCNY-1.63M · vs all stocks (USD)
Pre-tax Income
-50.73MCNYFY2025 · Dec 31, 2025Income Tax Expense
9.69MCNYFY2025 · Dec 31, 2025Net Income
-60.42MCNYFY2025 · Dec 31, 2025EBIT
-50.54MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
31.13MCNYFY2025 · Dec 31, 2025Research & Development
53.00MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
26.99MCNYFY2025 · Dec 31, 2025Other Operating Expenses
3.34MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
2.26MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
192.69KCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.9100CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.9100CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
55.36MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
55.36MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-60.42MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
10.04MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-33.01MCNYFY2025 · Dec 31, 2025Free Cash Flow
-59.50MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
104.40MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-60.42MCNYFY2025 · Dec 31, 2025Other Non-cash Items
1.89MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
12.93MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
12.59MCNYFY2025 · Dec 31, 2025Capital Expenditures
-26.50MCNYFY2025 · Dec 31, 2025Purchase of Investments
-231.00MCNYFY2025 · Dec 31, 2025Sale of Investments
210.76MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-46.74MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-16.25MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-9.50MCNYFY2025 · Dec 31, 2025Other Financing Charges
-3.18MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-28.94MCNYFY2025 · Dec 31, 2025Shares Outstanding
55.86MSharesUpdated Jul 16, 2026Float Shares
32.40MSharesUpdated Jul 16, 2026% Held by Insiders
37.68%vs all stocks
% Held by Institutions
13.15%vs all stocks
Total Cash (MRQ)
225.80MCNY33.47M · vs all stocks (USD)
Total Cash per Share (MRQ)
4.09CNYUpdated Jul 16, 2026Total Debt (MRQ)
2.44MCNY361.96K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0029xvs Biotechnology peers
Current Ratio (MRQ)
18.75xvs Biotechnology peers
Book Value per Share (MRQ)
15.22CNYUpdated Jul 16, 2026Total Assets
885.39MCNY131.24M · vs all stocks (USD)
Total Current Assets
427.79MCNYFY2025 · Dec 31, 2025Total Liabilities
39.17MCNYFY2025 · Dec 31, 2025Total Non-current Assets
457.60MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
8.36MCNYFY2025 · Dec 31, 2025Total Current Liabilities
30.81MCNYFY2025 · Dec 31, 2025Cash
104.96MCNYFY2025 · Dec 31, 2025Cash Equivalents
0.00CNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
104.96MCNYFY2025 · Dec 31, 2025Other Short-term Investments
120.28MCNYFY2025 · Dec 31, 2025Accounts Receivable
141.32MCNYFY2025 · Dec 31, 2025Inventory
32.39MCNYFY2025 · Dec 31, 2025Accounts Payable
12.68MCNYFY2025 · Dec 31, 2025Short-term Debt
1.27MCNYFY2025 · Dec 31, 2025Other Current Liabilities
939.96KCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
3.08MCNYFY2025 · Dec 31, 2025Common Stock (Book)
55.86MCNYFY2025 · Dec 31, 2025Retained Earnings
78.51MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
846.22MCNY125.44M · vs all stocks (USD)
Treasury Stock
17.03MCNYFY2025 · Dec 31, 202552-Week Low
19.32CNYUpdated Jul 16, 202652-Week High
36.00CNYUpdated Jul 16, 202652-Week Change
-15.67%vs all stocks
Beta
0.3410xvs all stocks
50-Day MA
24.95CNYUpdated Jul 16, 2026200-Day MA
27.83CNYUpdated Jul 16, 2026Avg 10-Day Volume
1.05MSharesUpdated Jul 16, 2026Avg 30-Day Volume
1.03MSharesUpdated Jul 16, 2026Diluted EPS (TTM)
-1.06CNYUpdated Jul 16, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)Notable
Debt-to-equity: 0.00Industry median: 0.09Industry P5: 0.00Peers compared: 261
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.78Profit Margin: -0.36
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $189.77M, lower than 95% of all stocks globallySignificant
Market cap (USD): 189,766,586.069Global P5: 269,387,740.27
Revenue is $24.13M, lower than 95% of all stocks globallySignificant
Revenue (USD): 24,133,577.698Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Anika Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tonix Pharmaceuticals Holding Corp.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Voyager Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Onward Medical
Tier 1ProductionApproval-Gated PipelineRule
Camp4 Therapeutics Corp.
Tier 1ProductionApproval-Gated PipelineRuleRisk
LENZ Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cabio Biotech Wuhan Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
TaiGen Biopharmaceuticals Holdings Limited
Tier 1ProductionApproval-Gated PipelineRuleRisk
RxSight Inc.
Tier 1ProductionApproval-Gated PipelineRule
MediWound Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
CIE Automotive India Ltd.
1 interpretationIndustry-Benchmarked ROA and Margin Elevated
Avery Dennison Corporation
1 interpretationIndustry-Benchmarked ROA and Margin Elevated
Prakash Industries Ltd.
1 interpretationIndustry-Benchmarked ROA and Margin Elevated